These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1130 related articles for article (PubMed ID: 10815935)

  • 1. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
    Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
    Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
    Némati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
    Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
    Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
    Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
    You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G
    Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adding a reverser (verapamil) to combined chemotherapy overrides resistance in small cell lung cancer xenografts.
    Arvelo F; Poupon MF; Bichat F; Grossin F; Bourgeois Y; Jacrot M; Bastian G; Le Chevalier T
    Eur J Cancer; 1995 Oct; 31A(11):1862-8. PubMed ID: 8541114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
    Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
    Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
    Unsal M; Erturk D
    Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide in small cell lung cancer.
    Einhorn LH
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):19-21. PubMed ID: 2539644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
    J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etoposide plus ifosfamide plus cisplatin in the treatment of small cell lung cancer.
    Sandler AB
    Semin Oncol; 1998 Feb; 25(1 Suppl 2):38-41. PubMed ID: 9535210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates.
    Poupon MF; Arvelo F; Goguel AF; Bourgeois Y; Jacrot M; Hanania N; Arriagada R; Le Chevalier T
    J Natl Cancer Inst; 1993 Dec; 85(24):2023-9. PubMed ID: 7902445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
    Quoix E; Breton JL; Gervais R; Wilson J; Schramel F; Cardenal F; Ross G; Preston A; Lymboura M; Mattson K
    Lung Cancer; 2005 Aug; 49(2):253-61. PubMed ID: 16022920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma.
    Tas F; Derin D; Guney N; Camlica H; Aydiner A; Topuz E
    Lung Cancer; 2007 Jul; 57(1):79-83. PubMed ID: 17383768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study.
    Ardizzoni A; Favaretto A; Boni L; Baldini E; Castiglioni F; Antonelli P; Pari F; Tibaldi C; Altieri AM; Barbera S; Cacciani G; Raimondi M; Tixi L; Stefani M; Monfardini S; Antilli A; Rosso R; Paccagnella A
    J Clin Oncol; 2005 Jan; 23(3):569-75. PubMed ID: 15659503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are we moving towards continuous treatment in small cell lung cancer (SCLC)?
    Van Zandwijk N
    Anticancer Res; 1994; 14(1B):309-11. PubMed ID: 8166473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.